Last reviewed · How we verify
FOLFOX/XELOX/Capecitabine
FOLFOX/XELOX regimens are chemotherapy combinations that inhibit thymidylate synthase and cause DNA damage to kill rapidly dividing cancer cells.
FOLFOX/XELOX regimens are chemotherapy combinations that inhibit thymidylate synthase and cause DNA damage to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.
At a glance
| Generic name | FOLFOX/XELOX/Capecitabine |
|---|---|
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Cytotoxic chemotherapy combination regimen |
| Target | Thymidylate synthase (5-FU component); DNA (oxaliplatin component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; XELOX substitutes capecitabine (an oral 5-FU prodrug) for intravenous 5-FU. 5-FU inhibits thymidylate synthase, disrupting DNA synthesis, while oxaliplatin creates platinum-DNA adducts causing cross-linking and apoptosis. These are standard cytotoxic chemotherapy regimens used in colorectal and gastric cancers.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Peripheral neuropathy
- Anemia
- Mucositis
- Hand-foot syndrome (capecitabine)
Key clinical trials
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer (PHASE3)
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (PHASE2)
- Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy. (PHASE4)
- Non-Operative Management and Early Response Assessment in Rectal Cancer (NA)
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (PHASE3)
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: